tradingkey.logo
tradingkey.logo
Suchen

Anika Therapeutics Inc

ANIK
Zur Watchlist hinzufügen
14.620USD
-0.110-0.75%
Handelsschluss 06/25, 16:00ETKurse um 15 Minuten verzögert
194.53MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Anika Therapeutics Inc Unternehmen

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

Anika Therapeutics Inc Informationen

BörsenkürzelANIK
Name des UnternehmensAnika Therapeutics Inc
IPO-datumMay 16, 1985
CEOBlanchard (Cheryl Renee)
Anzahl der mitarbeiter288
WertpapierartOrdinary Share
GeschäftsjahresendeMay 16
Addresse32 Wiggins Ave
StadtBEDFORD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01730-2315
Telefon17814579000
Websitehttps://anika.com/
BörsenkürzelANIK
IPO-datumMay 16, 1985
CEOBlanchard (Cheryl Renee)

Führungskräfte von Anika Therapeutics Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
42.57K
+6.40%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
20.40K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Susan L. N. Vogt
Ms. Susan L. N. Vogt
Independent Director
Independent Director
--
--
Mr. David B. Colleran, J.D.
Mr. David B. Colleran, J.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
--
--
Mr. John Bell (Jack) Henneman, III
Mr. John Bell (Jack) Henneman, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Stephen O. Richard
Mr. Stephen O. Richard
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
42.57K
+6.40%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
20.40K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Anika Therapeutics Inc?

Die fünf größten Anteilseigner von Anika Therapeutics Inc sind: Mr. Stephen D. (Steve) Griffin

Wie viele Institutionen halten Anteile an Anika Therapeutics Inc (ANIK)?

Mit Stand vom 2026Q1 halten 264 Institutionen Anteile an Anika Therapeutics Inc, mit einem Gesamtmarktwert von etwa 12.85M, was 96.55% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1611291.00 gestiegen.

Was ist die größte Einnahmequelle von Anika Therapeutics Inc?

Am 2026Q1 erzielte das Geschäft mit OEM Channel für Anika Therapeutics Inc den höchsten Umsatz in Höhe von 64.41M, was 57.09% des Gesamtumsatzes entspricht.
KeyAI